Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.265 -0.015 (-0.28%)
Streaming Delayed Price Updated: 2:52 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
2 Cathie Wood Stocks I'm Bullish On
These two next-gen biotechs could be outstanding buys for patient investors. 
Via The Motley Fool
2 AI Stocks That Aren't Worth the Hype
Even if you're bullish on AI, you may want to think twice about buying shares of these two companies. 
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?
On Monday, Cathie Wood-led Ark Invest made a notable move by selling nearly $4 million worth of NVIDIA Corp (NASDAQ:NVDA) shares. This ... 
Via Benzinga
Topics Artificial Intelligence
2 Cathie Wood Stocks That Could Deliver Exponential Returns
These two cutting-edge healthcare companies could be significantly undervalued right now. 
Via The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy?
This small-cap stock hopes to revolutionize drug discovery with the help of AI. 
Via The Motley Fool
AI Investing: 12 Possible Ways To Maximize Your Returns
It all comes down to playing it smart and doing your research and to help you with that we present 12 micro/small cap AI&R stocks with descriptions of their businesses and their price-to-sales ratios,... 
Via Talk Markets
Topics Artificial Intelligence
Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend
Ginkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend of tomorrow using the big data of today. 
Via InvestorPlace
3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
Cathie Wood is loading up on these healthcare stocks. 
Via The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
They're both liable to grow by a lot, but one of them is a safer bet in the near term. 
Via The Motley Fool
3 AI Drug Discovery Stocks to Watch
The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies. 
Via The Motley Fool
Topics Artificial Intelligence
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Find out why analysts have such high expectations for these stocks. 
Via The Motley Fool
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Where Will Recursion Pharmaceuticals Be in 3 Years?
This biotech could still be a long way from having a drug on the market in 2026. 
Via The Motley Fool
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months. 
Via The Motley Fool
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
These biotech stocks to buy and hold offer tremendous upside blending long-term potential with healthcare advances. 
Via InvestorPlace
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
The famous growth investor has been making some interesting stock moves lately. 
Via The Motley Fool
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
Both businesses have a lot to prove. 
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
Via Benzinga
Topics Artificial Intelligence
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
AI Bubble Stocks Deflating, Down 14% So Far In August
13 artificial intelligence and related stocks have dramatically outpaced the sector in general since the AI&R bubble began to inflate at the end of April. MTD, however, they have declined 13.6%, on... 
Via Talk Markets
Topics Artificial Intelligence
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M
Via Benzinga
Topics Earnings
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead
Via Benzinga
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing. 
Via InvestorPlace
3 Green Flags for Biotech Stocks in 2023 and Beyond
The industry is changing rapidly, and for the better. 
Via The Motley Fool
Cathie Wood's Ark Invest Continues To Sell Shopify Shares Amid Q2 Ripples
Via Benzinga
Cathie Wood's Ark Invest Buys $16M Worth Of Shares Of Flying Taxi Company Archer Aviation — Sells Shopify Stock Worth Millions
Via Benzinga
These 9 AI Stocks Are Up 95%, On Average, Since End Of April
Nine artificial intelligence and AI-related stocks, with market caps in excess of $2B, have advanced by +60% since the bubble began to develop at the end of April into early May, with an average... 
Via Talk Markets
Topics Artificial Intelligence
Every AI Stock Cathie Wood Owns, Ranked From Best to Worst
You can find some great AI investment opportunities by looking at the stocks in Wood's Ark Invest portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
3 Things About Recursion Pharmaceuticals That Smart Investors Know
Until it can get some recurring revenue going, it'll be a risky stock to buy. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.